A RON	GB 00 3593 Office	FG1/GE 00/03593
	PRIORITY DOCUMENT SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)	The Patent Office Concept House Cardiff Road Newport South Wales NP10 800 REC'D 0 5 OCT 2000 WIPO PCT


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that by virtue of an assignment registered under the Patents Act 1977, the application is now proceeding in the name as substituted.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before reregistration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

stains .

Dated 30 August 2000



GB9922171.5

By virtue of a direction given under Section of the Patents Act 1977, the application is proceeding in the name of

ASTRAZENECA AB, Incorporated in Sweden, S-151 85 Sodertalje, Sweden

[ADP No. 07822448003]

una ruge Blank (uspto)

••

.

;

÷

GB9922171.5

By virtue of a direction given under Section of the Patents Act 1977, the application is proceeding in the name of

ASTRAZENECA UK SIMITED Incorporated in the United Kingdom 15 Stanhope Gate LONDON 1 W1Y 6LN Unite PKingdom

[ADP No. 07810294001]

This Page Blank (uspto)

.

ž

0-	tents Form 1/77	The	of Comparis and and a second s
ra	tents Form 1/ / /	Patent	a stanting meriodes
	e Art 1077	21SEP99 E4 P01/7700 C	177988-2 D02934 0.00 ~ 9922171.5
R Se	equest for grant of a patent e the notes on the back of this form. You can also get	21 SEP 1999	The Patent Office
in (explanatory leaflet from the Patent Office to help fill in this form)		Cardiff Road Newport Gwent NP9 1RH
ι.	Your reference	PHM 99-140	
2.	Patent application number (The Patent Office will fill in this part)	9922171.5	
	Full name, address and postcode of the or of each applicant (underline all surnames)	Zeneca Limited 15 Stanhope Gate LONDON W1Y-610, GB	FILED 9 300.
	Patents ADP number (if you know it)	CTION 30 1.0 6254007002	
	and the state has the state she	·	<i>i</i>
	If the applicant is a corporate body, give the country/state of its incorporation		6
í.	 Patent application number (The Patent Office will fill in this part) Full name, address and postcode of the or of each applicant (underline all surnames) Patents ADP number (if you know it) If the applicant is a corporate body, give the country/state of its incorporation Title of the invention 	CHEMICAL COMPOUNDS	5
	Name of your agent (if you bave one)	CHEMICAL COMPOUNDS BILL, Kevin	5
<u>.</u>		BILL, Kevin AstraZeneca PLC Global Intellectual Property	
	Name of your agent (<i>if you bave one</i>) "Address for service" in the United Kingdom to which all correspondence should be sent	BILL, Kevin AstraZeneca PLC	y
	Name of your agent (<i>if you bave one</i>) "Address for service" in the United Kingdom to which all correspondence should be sent	BILL, Kevin AstraZeneca PLC Global Intellectual Property Mereside, Alderley Park,	y
	Name of your agent (if you bave one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	BILL, Kevin AstraZeneca PLC Global Intellectual Property Mereside, Alderley Park, Macclesfield, Cheshire, Sk	y <10 4TG, GB \scribe
	Name of your agent (<i>if you bave one</i>) "Address for service" in the United Kingdom to which all correspondence should be sent (<i>including the postcode</i>) Patents ADP number (<i>if you know it</i>) If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (<i>if you know tt</i>) the or	BILL, Kevin AstraZeneca PLC Global Intellectual Property Mereside, Alderley Park, Macclesfield, Cheshire, Sk 4469847002	y <10 4TG, GB wher Date of filing

This Page Blank (uspto)

Tinto wing memb y verale a	tato vaco alistoria.		
Do not count copies of the	he same document		
Continuatio	on sheets of this form	^	
. :	Description	36	 ,
	Claim(s)	<u> </u>	
	Abstract		
	Drawing(s)		
10. If you are also filing any o state how many against ea	of the following, ach item.		
	Priority documents		
Translations of	of priority documents		
Statement of in	nventorship and right		
	tent (Patents Form 7/77)		
to grant of a pat			
Request for pre	liminary examination rch (Patents Form 9/77)		
Request for pre and sea	rch (Patents Form 9/77)		· · ·
Request for pre and sea	liminary examination rch (Patents Form 9/77) ostantive examination (Patents Form 10/77)		

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs Lynda May Slack 01625 516173

dallare

Date

- 20 September 1999

Warning

After an application for a patent bas been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to probibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad witbout first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforeband in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them. b)
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate c) sbeet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it. e)

This Page Blank (uspto)

. .

CHEMICAL COMPOUNDS

- 1 -

The present invention relates to certain quinazoline derivatives for use in the treatment of certain diseases in particular to proliferative disease such as cancer and in the preparation of medicaments for use in the treatment of proliferative disease, to novel quinazoline compounds and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.

Cancer (and other hyperproliferative disease) is characterised by uncontrolled cellular proliferation. This loss of the normal regulation of cell proliferation often appears to occur as the result of genetic damage to cellular pathways that control progress through the cell cycle.

In eukaryotes, the cell cycle is largely controlled by an ordered cascade of protein phosphorylation. Several families of protein kinases that play critical roles in this cascade have now been identified. The activity of many of these kinases is increased in human tumours when compared to normal tissue. This can occur by either increased levels of expression of the protein (as a result of gene amplification for example), or by changes in expression of co activators or inhibitory proteins.

The first identified, and most widely studied of these cell cycle regulators have been the cyclin dependent kinases (or CDKs). Activity of specific CDKs at specific times is essential for both initiation and coordinated progress through the cell cycle For example, the CDK4 protein appears to control entry into the cell cycle (the G0-G1-S transition) by phosphorylating the retinoblastoma gene product pRb. This stimulates the release of the transcription factor E2F from pRb, which then acts to increase the transcription of genes necessary for entry into S phase . The catalytic activity of CDK4 is stimulated by binding to a partner protein, Cyclin D. One of the first demonstrations of a direct link between cancer and the cell cycle was made with the observation that the Cyclin D1 gene was amplified and cyclin D protein levels increased (and hence the activity of CDK4 increased) in many human tumours (Reviewed in Sherr, 1996, Science 274: 1672-1677; Pines, 1995, Seminars in Cancer Biology 6: 63-72). Other studies (Loda et al., 1997, Nature Medicine 3(2): 231-234; Gemma et al., 1996, International Journal of Cancer 68(5): 605-11; Elledge et al. 1996, Trends in Cell Biology 6; 388-392) have shown that negative regulators of CDK function are frequently

15

10

5

25

30

down regulated or deleted in human tumours again leading to inappropriate activation of these kinases.

More recently, protein kinases that are structurally distinct from the CDK family have
been identified which play critical roles in regulating the cell cycle and which also appear to
be important in oncogenesis. These include the newly identified human homologues of the *Drosophila* aurora and *Scerevisiae* Ipl1 proteins. *Drosophila* aurora and *Scerevisiae* Ipl1,
which are highly homologous at the amino acid sequence level, encode serine/threonine
protein kinases. Both aurora and Ipl1 are known to be involved in controlling the transition
from the G2 phase of the cell cycle through mitosis, centrosome function, formation of a
mitotic spindle and proper chromosome separation / segregation into daughter cells. The two
human homologues of these genes, termed aurora1 and aurora2, encode cell cycle regulated
protein kinases. These show a peak of expression and kinase activity at the G2/M boundary
(aurora2) and in mitosis itself (aurora1). Several observations implicate the involvement of
human aurora proteins , and particularly aurora2 in cancer. The aurora2 gene maps to

chromosome 20q13, a region that is frequently amplified in human tumours including both breast and colon tumours. Aurora2 may be the major target gene of this amplicon, since aurora2 DNA is amplified and aurora2 mRNA overexpressed in greater than 50% of primary human colorectal cancers. In these tumours aurora2 protein levels appear greatly elevated compared to adjacent normal tissue. In addition, transfection of rodent fibroblasts with human aurora2 leads to transformation, conferring the ability to grow in soft agar and form tumours in nude mice (Bischoff et al., 1998, The EMBO Journal. 17(11): 3052-3065). Other work (Zhou et al., 1998, Nature Genetics. 20(2): 189-93) has shown that artificial overexpression of aurora2 leads to an increase in centrosome number and an increase in aneuploidy.

Importantly, it has also been demonstrated that abrogation of aurora2 expression and function by antisense oligonucleotide treatment of human tumour cell lines (WO 97/22702 and WO 99/37788) eads to cell cycle arrest in the G2 phase of the cell cycle and exerts an antiproliferative effect in these tumour cell lines. This indicates that inhibition of the function of aurora2 will have an antiproliferative effect that may be useful in the treatment of human tumours and other hyperproliferative diseases.

30

A number of quinazoline derivatives have been proposed hitherto for use in the inhibition of various kinases. Examples of such proposals are included in WO 92/20642 and


- 2 -

- 3 -

EP-B-584222 which relates to bicyclic compounds which inhibit epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase, WO 95/15758 which describes the use of bis ring systems for the selective inhibition of CSF-1R tyrosine kinase activity, and WO 99/09016, WO 97/03069 and US 570158 which describe the use of certain quinazoline compounds as tyrosine kinase inhibitors in other contexts.

The applicants have found a series of compounds which inhibit the effect of the aurora2 kinase and which are thus of use in the treatment of proliferative disease such as cancer, in particular in such diseases such as colorectal or breast cancer where aurora 2 kinase is known to be active.

The present invention provides a compound of formula (I)



(I)

15

5

10

or a salt, ester or amide thereof;

where X is O, or S, S(O) or S(O)₂, NH or NR⁶ where R⁶ is hydrogen or C₁₋₆alkyl,; R⁵ is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom,

R¹, R², R³, R⁴ are independently selected from, halo, cyano, nitro, trifluoromethyl, C_{1.3}alkyl, -NR⁷R⁸ (wherein R⁷ and R⁸, which may be the same or different, each represents hydrogen or C_{1.3}alkyl), or -X¹R⁹ (wherein X¹ represents a direct bond, -O-, -CH₂-, -OCO-, carbonyl, -S-, -SO-, -SO₂-, -NR¹⁰CO-, -CONR¹¹-, -SO₂NR¹²-, -NR¹³SO₂- or -NR¹⁴- (wherein R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ each independently represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl), and R⁹ is selected from one of the following eighteen groups: 1) hydrogen or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino,

- 4 -

2) C1-salkylX²COR¹⁵ (wherein X² represents -O- or -NR¹⁶- (in which R¹⁵ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁶ represents C₁₋₃alkyl, -NR¹⁷R¹⁸ or -OR¹⁹ (wherein R¹⁷,

- R^{18} and R^{19} which may be the same or different each represents hydrogen, C_{1-3} alkyl or C_{1-3} 5 ,alkoxyC_{2.3}alkyl));
 - 3) C1. salkylX³R²⁰ (wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OCO-, -NR²¹CO-, -CONR²²-, -SO₂NR²³-, -NR²⁴SO₂- or -NR²⁵- (wherein R²¹, R²², R²³, R²⁴ and R²⁵ each independently represents hydrogen, $C_{1.3}$ alkyl or $C_{1.3}$ alkoxy $C_{2.3}$ alkyl) and R^{20} represents hydrogen, $C_{1.3}$ alkyl,
- cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 10 heteroatoms, selected independently from O, S and N, which C1.3alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C14 alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C1_4alkyl, C1_4hydroxyalkyl and C_{1} alkoxy);
- 4) $C_{1.5}$ alkylX⁴ $C_{1.5}$ alkylX⁵ R^{26} (wherein X⁴ and X⁵ which may be the same or different are each -15 O-, -S-, -SO-, -SO₂-, -NR²⁷CO-, -CONR²⁸-, -SO₂NR²⁹-, -NR³⁰SO₂- or -NR³¹- (wherein R²⁷, R²⁸, R²⁹, R³⁰ and R³¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R^{26} represents hydrogen or C₁₋₃alkyl);

5) R³² (wherein R³² is a 5-6-membered saturated heterocyclic group (linked via carbon or

國

- nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic 20 group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C14alkyl, C1 ⁴hydroxyalkyl, C_{14} alkoxy, C_{14} alkoxy C_{14} alkyl and C_{14} alkylsulphonyl C_{14} alkyl); 6) C₁ salkyl R^{32} (wherein R^{32} is as defined hereinbefore);
 - 7) $C_{2.5}$ alkenyl R^{32} (wherein R^{32} is as defined hereinbefore);

8) $C_{2,3}$ alkynylR³² (wherein R³² is as defined hereinbefore);

9) R³³ (wherein R³³ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C₁₄alkyl, C₁₄alkoxy,

C, hydroxyalkyl, C₁₄aminoalkyl, C₁₄alkylamino, C₁₄hydroxyalkoxy, carboxy, 30

trifluoromethyl, cyano, -CONR³⁴R³⁵ and -NR³⁶COR³⁷ (wherein R³⁴, R³⁵, R³⁶ and R³⁷, which may be the same or different, each represents hydrogen, C_{1-4} alkyl or C_{1-3} alkoxy C_{2-3} alkyl)); 10) C_{1-5} alkylR³³ (wherein R³³ is as defined hereinbefore);

11) $C_{2,5}$ alkenyl \mathbb{R}^{33} (wherein \mathbb{R}^{33} is as defined hereinbefore);

12) $C_{2,5}$ alkynyl R^{33} (wherein R^{33} is as defined hereinbefore);

13) C_{1.5}alkylX⁶R³³ (wherein X⁶ represents -O-, -S-, -SO-, -SO₂-, -NR³⁸CO-, -CONR³⁹-, -SO₂NR⁴⁰-, -NR⁴¹SO₂- or -NR⁴²- (wherein R³⁸, R³⁹, R⁴⁰, R⁴¹ and R⁴² each independently represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and R³³ is as defined hereinbefore);
14) C_{2.5}alkenylX⁷R³³ (wherein X⁷ represents -O-, -S-, -SO-, -SO₂-, -NR⁴³CO-, -CONR⁴⁴-, -SO₂NR⁴⁵-, -NR⁴⁶SO₂- or -NR⁴⁷- (wherein R⁴³, R⁴⁴, R⁴⁵, R⁴⁶ and R⁴⁷ each independently represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and R³³ is as defined hereinbefore);
15) C_{2.5}alkynylX⁸R³³ (wherein X⁸ represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁸CO-, -CONR⁴⁹-, -SO₂NR⁵⁰-, -NR⁵¹SO₂- or -NR⁵²- (wherein R⁴⁸, R⁴⁹, R⁵⁰, R⁵¹ and R⁵² each independently represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and R³³ is as defined hereinbefore);
16) C_{1.3}alkylX⁹C_{1.3}alkylR³³ (wherein X⁹ represents -O-, -S-, -SO-, -SO₂-, -NR⁵³CO-, -CONR⁵⁴-, -SO₂NR⁵⁵-, -NR⁵⁶SO₂- or -NR⁵⁷- (wherein R⁵³, R⁵⁴, R⁵⁵, R⁵⁶ and R⁵⁷ each independently represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and R³³ is as defined hereinbefore);
16) C_{1.3}alkylX⁹C_{1.3}alkylR³³ (wherein X⁹ represents -O-, -S-, -SO-, -SO₂-, -NR⁵³CO-, -CONR⁵⁴-, -SO₂NR⁵⁵-, -NR⁵⁶SO₂- or -NR⁵⁷- (wherein R⁵³, R⁵⁴, R⁵⁵, R⁵⁶ and R⁵⁷ each independently represents hydrogen, C_{1.3}alkyl or C_{1.3}alkoxyC_{2.3}alkyl) and R³³ is as defined hereinbefore); and 17) C_{1.3}alkylX⁹C_{1.3}alkylR³² (wherein X⁹ and R²⁸ are as defined hereinbefore); and R¹ and R⁴ may additionally be hydrogen.

In this specification the term 'alkyl' when used either alone or as a suffix includes straight chained, branched structures. Unless otherwise stated, these groups may contain up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. Similarly the terms "alkenyl" and "alkynyl" refer to unsaturated straight or branched structures containing for example from 2 to 10, preferably from 2 to 6 carbon atoms. Cyclic moieties such as cycloalkyl, cycloalkenyl and cycloalkynyl are similar in nature but have at least 3 carbon atoms. Terms such as "alkoxy" comprise alkyl groups as is understood in the art.

The term "halo" includes fluoro, chloro, bromo and iodo. References to aryl groups include aromatic carbocylic groups such as phenyl and naphthyl. The term "heterocyclyl" includes aromatic or non-aromatic rings, for example containing from 4 to 20, suitably from 5 to 8 ring atoms, at least one of which is a heteroatom such as oxygen, sulphur or nitrogen. Examples of such groups include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl,

15

10

25

30

10

- 6 -

thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzoxazolyl, benzothienyl or benzofuryl.

"Heteroaryl" refers to those groups described above which have an aromatic character. The term "aralkyl" refers to aryl substituted alkyl groups such as benzyl.

Other expressions used in the specification include "hydrocarbyl" which refers to any structure comprising carbon and hydrogen atoms. For example, these may be alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkoxy, aralkyl, cycloalkyl, cycloalkenyl or cycloalkynyl.

The term "functional group" refers to reactive substituents such as nitro, cyano, halo, oxo, = $CR^{78}R^{79}$, $C(O)_xR^{77}$, OR^{77} , $S(O)_yR^{77}$, $NR^{78}R^{79}$, $C(O)NR^{78}R^{79}$, $OC(O)NR^{78}R^{79}$, = NOR^{77} , - $NR^{77}C(O)_xR^{78}$, $-NR^{77}CONR^{78}R^{79}$, $-N=CR^{78}R^{79}$, $S(O)_yNR^{78}R^{79}$ or $-NR^{77}S(O)_yR^{78}$ where R^{77} , R^{78} and R^{79} are independently selected from hydrogen or optionally substituted hydrocarbyl, or R^{78} and R^{79} together form an optionally substituted ring which optionally contains further heteroatoms such as $S(O)_y$ oxygen and nitrogen, x is an integer of 1 or 2, y is 0 or an integer of 1-3.

Suitable optional substituents for hydrocarbyl groups R^{77} , R^{78} and R^{79} include halo, perhaloalkyl such as trifluoromethyl, mercapto, hydroxy, carboxy, alkoxy, heteroaryl, heteroaryloxy, alkenyloxy, alkynyloxy, alkoxyalkoxy, aryloxy (where the aryl group may be substituted by halo, nitro, or hydroxy), cyano, nitro, amino, mono- or di-alkyl amino, oximino or S(O), where y is as defined above.

20

5

10

15

Preferably R^1 and R^4 are hydrogen.

In a preferred embodiment, at least one group R^2 or R^3 , preferably R^3 , comprises a chain of at least 3 and preferably at least 4 optionally substituted carbon atoms or heteroatoms such as oxygen, nitrogen or sulphur. Most preferably the chain is substituted by a polar group which assists in solubility.

Suitably R^3 is a group XR^{11} . Preferably in this case, X^1 is oxygen and R^{11} is selected from a group of formula (1) or (10) above. Particular groups R^{11} are those in group (1) above, especially alkyl such as methyl or halo subsituted alkyl, or those in group (10) above. In one preferred embodiment, at least one of R^2 or R^3 is a group $OC_{1.5}$ alkyl R^{33} and R^{33} is a

30 heterocyclic ring such as an N-linked morpholine ring such as 3-morpholinopropoxy.



- 7 -

Suitably R^2 is selected from, halo, cyano, nitro, trifluoromethyl, $C_{1.3}$ alkyl, -NR⁹R¹⁰ (wherein R⁹ and R¹⁰, which may be the same or different, each represents hydrogen or $C_{1.3}$ alkyl), or a group -X¹R¹¹. Preferred examples of -X¹R¹¹ for R² include those listed above in relation to R³.

5

10

15

20

Other examples for R^2 and R^3 include methoxy or 3,3,3-trifluoroethoxy. Preferably X is NH or O and is most preferably NH.

Suitably R⁵ is optionally substituted pyridine or optionally substituted pyrimidine and is preferably optionally substituted pyrimidine.

Most preferably, R^5 is a substituted pyridine or substituted pyrimidine group.

Suitable substituents for the pyridine or pyrimidine groups R⁵ include optionally substituted hydrocarbyl, optionally substituted heterocylyl or a functional group as defined above.

In particular, R⁵ is substituted by one or more groups selected from halo, C₁₋₄alkyl, optionally substituted C₁₋₆ alkoxy, C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkylcarbamoyl, <u>N,N-di</u>(C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, <u>N-C₁₋₄alkylaminosulphonyl, N,N-di</u>(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, and a saturated heterocyclic group selected

25

30

from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C_{1-4} alkoxycarbonyl.


Suitably R⁵ is substituted with at least one group which has at least 4 atoms which may be carbon or heteroatoms forming a chain. A particular example of such a substituent is

PHM 99-140

- 8 -

optionally subtituted alkoxy. Suitable substitutents for the alkoxy group include those listed above in relation to R^{77} , R^{78} and R^{79} .

A further particular substituent group for R^5 is a group of sub-formula (II)



5

where q is 0, 1, 2, 3 or 4; R⁷⁰ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, amino, N-C₁₋₆alkylamino, N,N-(C₁₋₆alkyl)₂amino, hydroxyC₂₋₆alkoxy, C₁₋₆alkoxyC₂₋₆alkoxy, aminoC₂₋₆alkoxy, N-C₁₋₆alkylaminoC₂₋₆alkoxy, N,N-(C₁₋₆alkyl)₂aminoC₂₋₆alkoxy or C₃₋₇cycloalkyl,

or R^{70} is of the Formula (III):

—K—J (III)

wherein J is aryl, heteroaryl or heterocyclyl and K is a bond, oxy, imino, N-(C₁₋₆alkyl)imino, oxyC₁₋₆alkylene, iminoC₁₋₆alkylene, N-(C₁₋₆alkyl)iminoC₁₋₆alkylene, -NHC(O) -, -SO₂NH-,

-NHSO₂- or -NHC(O)-C₁₋₆alkylene-,
and any aryl, heteroaryl or heterocyclyl group in a R⁷⁰ group may be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, -O-(C₁₋₃alkyl)-O-, C₁₋₆alkylS(O)_n- (wherein n is 0-2), N-C₁₋₆alkylamino,

20 $N,N-(C_{1-6}alkyl)_2amino, C_{1-6}alkoxycarbonyl, N-C_{1-6}alkylcarbamoyl, N,N-(C_{1-6}alkyl)_2carbamoyl, C_{2-6}alkanoyl, C_{1-6}alkanoyloxy, C_{1-6}alkanoylamino, N-C_{1-6}alkylsulphamoyl, N,N-(C_{1-6}alkyl)_2sulphamoyl, C_{1-6}alkylsulphonylamino and C_{1-6}alkylsulphonyl-N-(C_{1-6}alkyl)amino,$

or any aryl, heteroaryl or heterocyclyl group in a R⁷⁰ group may be optionally substituted with one or more groups of the Formula (IV):

$$-B^{\perp}(CH_2)_{p}^{-}A^{1}$$
 (IV)

wherein A¹ is halo, hydroxy, C₁₋₆alkoxy, cyano, amino, N-C₁₋₆alkylamino, $N,N-(C_{1-6}alkyl)_2$ amino, carboxy, C₁₋₆alkoxycarbonyl, carbamoyl, N-C₁₋₆alkylcarbamoyl or

10

15

N,*N*-(C_{1-6} alkyl)₂carbamoyl, p is 1 - 6, and B¹ is a bond, oxy, imino, *N*-(C_{1-6} alkyl)imino or -NHC(O)-, with the proviso that p is 2 or more unless B¹ is a bond or -NHC(O)-; or any aryl, heteroaryl or heterocyclyl group in a R⁷⁰ group may be optionally substituted with one or more groups of the Formula (IB'):

5

15

20

 $-E^{1}D^{1}$ (V)

wherein D¹ is aryl, heteroaryl or heterocyclyl and E¹ is a bond, $C_{1-\delta}$ alkylene, $oxyC_{1-\delta}$ alkylene, oxy, imino, *N*-($C_{1-\delta}$ alkyl)imino, imino $C_{1-\delta}$ alkylene, *N*-($C_{1-\delta}$ alkyl)-imino $C_{1-\delta}$ alkylene, $C_{1-\delta}$ alkylene- $oxyC_{1-\delta}$ alkylene, $C_{1-\delta}$ alkylene-imino $C_{1-\delta}$ alkylene, $C_{1-\delta}$ alkylene-*N*-($C_{1-\delta}$ alkyl)imino $C_{1-\delta}$ alkylene, -NHC(O)-, -NHSO₂-, -SO₂NH- or -NHC(O)- $C_{1-\delta}$ alkylene-, and any aryl,

heteroaryl or heterocyclyl group in a substituent on R^4 may be optionally substituted with one or more groups selected from hydroxy, halo, $C_{1-\delta}$ alkyl, $C_{1-\delta}$ alkoxy, carboxy,

 C_{1-6} alkoxycarbonyl, carbamoyl, N- C_{1-6} alkylcarbamoyl, N- $(C_{1-6}$ alkyl)₂carbamoyl, C₂₋₆alkanoyl, amino, N- C_{1-6} alkylamino and N,N- $(C_{1-6}$ alkyl)₂amino,


and any C_{3-7} cycloalkyl or heterocyclyl group in a \mathbb{R}^{70} group may be optionally substituted with one or two oxo or thioxo substituents,

and any of the R⁷⁰ groups defined hereinbefore which comprises a CH₂ group which is attached to 2 carbon atoms or a CH₃ group which is attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group a substituent selected from hydroxy, amino, C₁₋₆alkoxy, N-C₁₋₆alkylamino, N,N-(C₁₋₆alkyl)₂amino and heterocyclyl.

A preferred example of a substituent of formula (V) is a group where q is 0.

A particular example of a group R^{70} in formula (II) is phenyl.

Another preferred substituent group for R⁵ is a group of formula (VI)



where R^{71} and R^{72} are independently selected from hydrogen or C_{14} alkyl, or R^{71} and R^{72} together form a bond, and R^{73} is a group OR^{74} , $NR^{75}R^{76}$ where R^{74} , R^{75} and R^{76} are independently selected from optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R^{75} and R^{76} may additionally form together with the nitrogen atom to

- 10 -

which they are attached, an aromatic or non-aromatic heterocyclic ring which may contain further heteroatoms.

Suitable optional substitutents for hydrocarbyl or heterocyclic groups R⁷⁴, R⁷⁵ and R⁷⁶ include functional groups as defined above. Heterocyclic groups R⁷⁴, R⁷⁵ and R⁷⁶ may further be substituted by hydrocarbyl groups.

In particular, R^{71} and R^{72} in sub-formula (VI) are hydrogen.

Particular examples of \mathbb{R}^{73} are groups $O\mathbb{R}^{74}$ where \mathbb{R}^{74} is C_{14} alkyl.


Further examples of \mathbb{R}^{73} are groups of formula $\mathbb{NR}^{75}\mathbb{R}^{76}$ where one of \mathbb{R}^{75} or \mathbb{R}^{76} is hydrogen and the other is optionally substituted \mathbb{C}_{1-6} alkyl, optionally substituted aryl or optionally substituted heterocyclyl.

In particular, one of \mathbb{R}^{75} or \mathbb{R}^{76} is hydrogen and the other is C_{1-6} alkyl optionally substituted with trifluoromethyl, C_{1-3} alkoxy such as methoxy, cyano, thio C_{1-4} alkyl such as methylthio, or heterocyclyl optionally substituted with hydrocarbyl, such as indane, furan optionally substituted with C_{1-4} alkyl such as methyl.

In another embodiment, one of \mathbb{R}^{75} or \mathbb{R}^{76} is hydrogen and the other is an optionally substituted heterocyclic group such as pyridine, or a phenyl group optionally substituted with for example one or more groups selected from halo, nitro, alkyl such as methyl, or alkoxy such as methoxy.

Where possible, the group R^5 may have a second substitutent in particular halo, C_{1-4} -alkoxy such as methoxy, or ethoxy, cyano, trifluoromethyl, or phenyl. Preferably any second substituent is a small group.

Suitably, at least one substituent is positioned at the para position on the ring R^5 . Thus suitable groups R^5 include compounds of sub-formulae




10

15

20



- 11 -



where R⁸⁰ and R⁸¹ are substituent groups as described above and in particular R⁸⁰ is a large substitutent of a chain of at least 4 atoms, in particular a group of sub-formula (II) or sub-formula (VI) and R⁸¹ is a small substitutent such as halo, C₁₋₄alkoxy such as methoxy, or ethoxy, cyano or trifluoromethyl, or phenyl.

Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts such as methanesulfonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. Where the compound of formula (I) includes an acid functionality, salts may be base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine. A preferred pharmaceutically acceptable salt is a sodium salt.

15

20

25

5

10

An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.

Suitable pharmaceutically acceptable esters for carboxy include $C_{1-\delta}$ alkyl esters such as methyl or ethyl esters, $C_{1-\delta}$ alkoxymethyl esters for example methoxymethyl,

 $C_{1-\delta}$ alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C_{3-8} cycloalkoxy-carbonyloxy C_{1-6} alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C1.salkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the

- 12 -

parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and


N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

Suitable amides are derived from compounds of formula (I) which have a carboxy group which is derivatised into an amide such as a N-C₁₋₆alkyl and N,N-di-

 $(C_{1-\delta}alkyl)$ amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethylamide.

Esters which are not *in vivo* hydrolysable may be useful as intermediates in the production of the compounds of formula (I).

Particular examples of compounds of formula (I) are set out in Table 1



Compound No.	R ²	R ³	R ⁵
1	OCH3	OCH ₃	
2	OCH3	OCH ₃	H O
3	OCH ₃	OCH3	
4	OCH ₃	_0N0	Ĥ

10


PHM 99-140



- 13 -	
--------	--

5	OCH ₃	OCH ₂ CF ₃	
6	OCH3	~0~~~N~~	H N N N N N N N N N N N N N N N N N N N
7	OCH3	_0N	
8	OCH3	~°~~~^^	N CI
9	OCH ₃	OCH ₂ C ₆ H ₅	
10	OCH ₃	OCH ₂ C ₆ H ₅	

Compounds of formula (I) may be prepared by various methods which would be apparent from the literature. For example compounds of formula (I) may be prepared by reacting a compound of formula (VII)



where R^1 , R^2 , R^3 , and R^4 are as defined in relation to formula (I) and R^{85} is a leaving group, with a compound of formula (VIII)

'5

H-X-R⁵ (VIII)

where X and R^5 are as defined in relation to formula (I). Suitable leaving groups for R^{85} include halo such as chloro, mesylate and tosylate. The reaction is suitably effected in an organic solvent such as an alcohol like isopropanol, at elevated temperatures, conveniently at the reflux temperature of the solvent.

5

Compounds of formula (VII) and (VIII) are either known compounds or they can be derived from known compounds by conventional methods. For example, where in the compound of formula (VIII), R⁵ carries a substitutent group R⁸⁰, this may be introduced into the ring using known chemistry. For example, compounds of formula (IX) where X is an NH group may be prepared by reduction of a compound of formula (IX)

 $O_2 N-R^5$ (IX)


for example by reaction with hydrogen in the presence of a catalyst such as a palladium catalyst or by reaction with a reducing agent such as sodium hydrosulphite.

15


25

10

Compounds of formula (IX) where R^5 is a group of formula (i), (ii), (iii), (iv) or (v) above and R^{80} is a group of formula (II) above can be prepared by reacting a compound of formula (X)



where \mathbb{R}^{81} is as defined above and Y_1 , Y_2 and Y_3 are selected from N, CH or CR⁸¹ as appropriate, with a compound of formula (XI)



where R^{70} and q are as defined in relation to sub-formula (II) and R^{88} is a leaving group such as halo. The reaction is suitably effected in the presence of a base such as pyridine at elevated temperatures, conveniently at the reflux temperature of the solvent.

5

10

15

20

- 15 -

Compounds of formula (I) are inhibitors of aurora 2 kinase. As a result, these compounds can be used to treat disease mediated by these agents, in particular proliferative disease.

According to a further aspect of the invention there is provided a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, for use in a method of treatment of the human or animal body by therapy. In particular, the compounds are used in methods of treatment of proliferative disease such as cancer and in particular cancers such as colorectal or breast cancer where aurora 2 is upregulated.

According to a further aspect of the present invention there is provided a method for inhibiting aurora 2 kinase in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.

The invention also provides a pharmaceutical composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof, in combination with at pharmaceutically acceptable carrier. Preferred compounds of formula (I) for use in the compositions of the invention are as described above.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

25

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

30

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium

PHM 99-140

carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl <u>p</u>-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the

- 16 -

gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents

10

15

5

20

25

PHM 99-140

5

10

15

0

may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

- 17 -

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

25

Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

30

Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a

- 18 -

conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30μ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the Formula I are useful in

15

20

25

30

10

treating diseases or medical conditions which are due alone or in part to the effects of aurora 2 kinase.

- 19 -

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

A further aspect of the invention comprises a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, for use in the preparation of a medicament for the treatment of proliferative disease. Preferred compounds of formula (I) for this purpose are as described above.

15

20

10

5

The following Examples illustrate the invention.

Example 1

Preparation of Compound No. 1 in Table 1

A solution of 2-(N-benzoyl) 2,5-diaminopyrimidine (91 mg, 0.43 mmol) and 4-chloro-6,7-dimethoxyquinazoline (97 mg, 0.43 mmol), in isopropanol (200 ml) was heated at reflux for 3 hours before the reaction was allowed to cool to ambient temperature. The solid which had precipitated was collected by suction filtration and washed with diethyl ether (2 x 50 ml). Drying of this material yielded the title compound (109 mg, 58 % yield) as a white solid : ¹H-NMR (DMSO d₆) : 11.79 (s, 1H), 11.11 (s, 1H), 9.11 (s, 1H), 8.88 (s, 1H), 8.41 (s, 1H), 7.98 (d, 2H, J = 8 Hz), 7.48-7.64 (m, 3H), 7.36 (s, 1H), 4.04 (s, 3H), 3.99 (s, 3H) : MS (-ve ESI) : 403 (M-H)⁺.

2-(N-Benzoyl) 2,5-diaminopyrimidine, used as the starting material was obtained as follows :
a) Benzoyl chloride (0.92 ml, 7.93 mmol) was added dropwise to a stirred solution of 2amino-5-nitropyrimidine (1.00 g, 7.14 mmol) in pyridine (20 ml) and the reaction was heated

30

PHM 99-140

at reflux for 4 hours under an inert atmosphere. The reaction was allowed to cool to ambient temperature, poured into water (200 ml) and allowed to stand for 16 hours. The solid was collected by suction filtration, washed with water (3 x 20 ml) and dried *in vacuo*. An oily residue on the surface of the aqueous phase was dissolved in dichloromethane (50 ml) and then

- 5 purified by flash chromatography on silica gel, eluting with 1-3% methanol. The two materials were identical and yielded 2-(N-benzoyl) 2-amino-5-nitropyrimidine (826 mg, 47 % yield) as a white solid :
 - ¹H-NMR (DMSO d_6) : 11.73 (s, 1H), 9.43 (s, 1H), 7.96 (d, 2H, J = 8 Hz), 7.47-7.65 (m, 3H) : MS (-ve ESI) : 243 (M-H)⁻,
- 10 MS (+ve ESI) : $245 (M+H)^+$.
 - b) 10% Platinum on carbon (71 mg, 0.036 mmol) was added to a solution 2-(N-benzoyl)
 2-amino-5-nitropyrimidine (733 mg, 3.00 mmol) in ethanol (100 ml) at ambient temperature
 and the reaction stirred for 1 hour under an atmosphere of hydrogen. The reaction was filtered
 through a pad of celite and the solvents were evaporated *in vacuo*. Purification by flash
- chromatography o silica gel, eluting with 5% methanol in dichloromethane yielded 2-(N-benzoyl) 2,5-diaminopyrimidine (91 mg, 14 % yield) as white solid :
 ¹H-NMR (DMSO d₆) : 8.63 (s, 1H), 8.14 (s, 2H), 7.90 (d, 2H, J = 8 Hz), 7.42-7.56 (m, 3H),

3.76 (s, 1H) :

MS (-ve ESI) : 213 (M-H)⁻,

20 MS (+ve ESI) : $215 (M+H)^+$.

4-Chloro-6,7-dimethoxyquinazoline, used as the starting material was obtained as follows :

a) A mixture of 4,5-dimethoxyanthranilic acid (19.7g, 100 mmol) and formamide (10ml) was heated at 190 °C for 5 hours. The mixture was allowed to cool to approximately 80 °C and water (50ml) was added. The mixture was then allowed to stand at ambient temperature

25 for 3 hours. Collection of the solid by suction filtration, followed by washing with water (2 x 50 ml) and drying in vacuo, yielded 6,7-dimethoxy-3,4-dihydroquinazolin-4-one (3.65g, 18 % yield) as a white solid.

¹H-NMR (DMSO d₆) : 12.10 (s, 1H), 7.95 (s, 1H), 7.42 (s, 1H), 7.11 (s, 1H), 3.88 (s, 3H), 3.84 (s, 3H) :

30 MS (-ve ESI) : $205 (M-H)^{-}$.

- 20 -

PHM 99-140

- 21 -

b) Dimethylformamide (0.2 ml) was added dropwise to a solution of 6,7-dimethoxy-3,4dihydro-quinazolin-4-one (10.0 g, 48.5 mmol) in thionyl chloride (200ml) and the reaction was heated at reflux for 6 hours. The reaction was cooled, excess thionyl chloride was removed *in vacuo* and the residue was azeotroped with toluene (2 x 50 ml) to remove the last of the thionyl chloride. The residue was taken up in dichloromethane (550 ml), the solution was washed with saturated aqueous sodium hydrogen carbonate solution (2 x 250 ml) and the organic phase was dried over magnesium sulphate. Solvent evaporation *in vacuo* yielded 4chloro-6,7-dimethoxyquinazoline (10.7 g, 98 % yield) as a white solid : ¹H-NMR (DMSO d₆) : 8.86 (s, 1H), 7.42 (s, 1H), 7.37 (s, 1H), 4.00 (s, 3H), 3.98 (s, 3H) : MS (+ve ESI) : 225 (M-H)⁺.

Example 2

5

'n

Preparation of Compound No. 2 in Table 1

An analogous reaction to that described in example 1, but starting with 2-(N-benzoyl)
2,5-diaminopyridine (128 mg, 0.60 mmol) and 4-chloro-6,7-dimethoxyquinazoline (135 mg, 0.60 mmol), yielded the title compound (182 mg, 69 % yield) as a pale-yellow solid :
¹H-NMR (DMSO d₆) : 11.54 (s, 1H), 10.90 (s, 1H), 9.11 (s, 1H), 8.84 (s, 1H), 8.74 (d, 1H, J = 2 Hz), 8.36 (s, 1H), 8.30 (d, 1H, J = 8 Hz), 8.19 (dd, 1H, J = 2,8 Hz), 8.05 (d, 1H, J = 8 Hz), 7.48-7.63 (m, 3H), 7.35 (s, 1H), 4.03 (s, 3H), 4.00 (s, 3H) :
MS (-ve ESI) : 400 (M-H)⁺, MS (+ve ESI) : 402 (M+H)⁺.

2-(N-Benzoyl) 2,5-diaminopyridine, used as the starting material was obtained as follows :

a) A mixture of 2-amino-5-nitropyridine (2.00 g, 14.4 mmol) and benzoyl chloride (1.90
ml, 15.9 mmol) was heated in pyridine (40 ml) at reflux for 4 hours under an inert atmosphere. The reaction was allowed to cool to ambient temperature, was poured into water (400 ml) and the precipitated solid was collected by suction filtration. Washing of the solid with water (3 x 100 ml) drying *in vacuo*, 2-(N-benzoyl) 2-amino-5-nitropyridine (3.16 g, 90 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 11.49 (s, 1H), 9.23 (d, 1H, J = 2 Hz), 8.65 (dd, 1H, J = 2,8 Hz), 8.43 (d, 1H, J = 8 Hz), 8.03 (d, 1H, J = 8 Hz), 7.50-7.65 (m, 3H) :

- 22 -

MS (-ve ESI) : 242 (M-H)⁻,

MS (+ve ESI) : $244 (M+H)^{+}$.

b) Sodium hydrosulphite (1.18 g, 6.76 mmol) was added portion-wise to a solution 2-(Nbenzoyl) 2-amino-5-nitropyridine (329 mg, 1.35 mmol) in a mixture of ethanol (25 ml) and

- 5 water at reflux. The reaction was heated at reflux for 20 minutes, cooled to ambient temperature and the ethanol was removed *in vacuo*. The residue was partitioned between water (5 ml) and ethyl acetate (25 ml), the organic layer was separated and the aqueous phase was extracted with more ethyl acetate (2 x 25 ml). Drying of the combined organic layers over magnesium sulphate, followed by solvent evaporation *in vacuo*, yielded 2-(N-benzoyl) 2,5-
- diaminopyridine (128 mg, 44 % yield) as a pale-yellow solid :
 ¹H-NMR (DMSO d₆) : 10.26 (s, 1H), 7.99 (d, 2H, J = 8 Hz), 7.79 (d, 1H, J = 8 Hz), 7.74 (d, 1H, J = 2 Hz), 7.43-7.56 (m, 3H), 7.03 (dd, 1H, J = 2,8 Hz), 5.20 (s, 1H) :
 MS (+ve ESI) : 214 (M+H)⁺.

15 Example 3 - (ZM272450) IPC

An analogous reaction to that described in example 1, but starting with 2-n-butoxy-5aminopyridine (83 mg, 0.50 mmol) and 4-chloro-6,7-dimethoxyquinazoline (135 mg, 0.60 mmol), yielded the title compound (122 mg, 61 % yield) as a yellow solid : ¹H-NMR (DMSO d₆) : 11.38 (s, 1H), 8.77 (s, 1H), 8.39 (d, 1H, J = 7 Hz), 8.27 (s, 1H), 7.96 (dd, 1H, J = 1,7 Hz), 7.31 (s, 1H), 6.91 (d, 1H, J = 8 Hz), 4.27 (t, 1H, J = 7 Hz), 4.00 (s, 3H), 3.98 (s, 3H), 1.71 (qu, 2H, J = 7 Hz), 1.44 (qu, 2H, J = 7 Hz), 0.93 (t, 3H, J = 7 Hz) : MS (-ve ESI) : 353 (M-H)', MS (+ve ESI) : 354 (M+H)⁺.

25 Example 4 - (ZM331346) IPC

An analogous reaction to that described in example 1, but starting with 2-amino-5chloropyridine (57 mg, 0.50 mmol) and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline, (187 mg, 0.50 mmol), yielded the title compound (87 mg, 37 % yield) as a pale yellow solid :

5

10

¹H-NMR (DMSO d₆) : 8.85 (s, 1H), 8.58 (d, 1H), 8.30 (s, 1H), 8.29 (d, 1H), 8.05 (m, 1H), 7.42 (s, 1H), 4.32 (t, 2H), 4.0 (s, 3H), 3.98 (m, 2H), 3.8 (t, 2H), 3.01-3.30 (m, 6H), 2.35 (m, 2H) ;

- 23 -

MS (+ve ESI) : $430 (M+H)^{+}$.

4-Chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline, used as the starting material, was obtained as follows :

a) A mixture of morpholine (261 ml, 3.00 mol) and 1-bromo-3-chloropropane (148 ml, 1.50 mol) in toluene (900 ml) was stirred for 18 hours at ambient temperature. Additional 1-bromo-3-chloropropane (25 ml, 0.25 mol) was added, the reaction was stirred for a further 1 hour and then filtered to remove the precipitated solid before the filtrate was concentrated *in vacuo*. Distillation of the crude oil yielded N-(3-chloropropyl)morpholine (119.3 g, 49 % yield) as the fraction boiling at 70 - 80 °C / 2.6 mmHg :

¹H-NMR (DMSO d₆) : 3.65 (t, 2H), 3.55 (m, 4H), 2.4 (t, 2H), 2.39 (m, 4H), 1.85 (m, 2H) : MS (+ve ESI) : 164 (M+H)⁺.

b) N-(3-Chloropropyl)morpholine (90 g, 0.55 mol) was added dropwise, over 30 minutes, to a solution of ethyl vanillate (98 g, 0.50 mol) and powdered potassium carbonate (104 g, 0.75 mol) in dimethylformamide (300 ml) at 80 °C. The reaction was heated at 80 °C for 90 minutes, cooled to ambient temperature, filtered and the filtrate concentrated *in vacuo*. The crude product was taken up in diethyl ether (1000 ml), filtered and washed with water (2 x 200 ml) and brine (200 ml). Solvent evaporation in vacuo yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate (161.5 g, 100 % yield) as a pale yellow oil which crystallised on standing to afford a pale yellow solid :

¹H-NMR (DMSO d₆) : 7.55 (dd, 1H), 7.4 (d, 1H), 7.05 (d, 1H), 4.3 (q, 2H), 4.05 (t, 2H), 3.8 (s, 3H), 3.55 (m, 4H), 2.4 (t, 2H), 2.35 (m, 4H), 1.9 (m, 2H), 1.3 (t, 3H) :

25 MS (-ve ESI) : $324 (M-H)^{-}$,

c) Concentrated sulphuric acid (110 ml) and concentrated nitric acid (19.0 ml, 0.289 mol) were added cautiously, over a 50 minute period, to a two-phase system containing a stirred solution of ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate (76.5 g, 0.237 mol) in dichloromethane (600 ml), acetic acid (300 ml) and water (70 ml) at 5 °C. The reaction was

30

allowed to warm to ambient temperature over 18 hours, the aqueous phase was separated, and the aqueous phase was taken to pH 9 by addition of 40% aqueous sodium hydroxide solution 5

- 24 -

(775 ml). Extraction of the aqueous phase with dichloromethane (3 x 600 ml) and subsequent solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate (141.3 g, 86 % yield) as a yellow gum :

¹H-NMR (CDCl₃) : 7.5 (s, 1H), 7.1 (s, 1H), 4.4 (q, 2H), 4.2 (t, 2H), 4.0 (s, 3H), 3.7 (m, 4H), 2.5 (t, 2H), 2.45 (m, 4H), 2.05 (m, 2H), 1.4 (t, 3H) :

MS (+ve ESI) : $369 (M+H)^{+}$.

d) A suspension of ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate (132.2 g, 359 mmol) and 10% palladium on carbon (3.0 g) in a mixture of ethanol (200 ml) and ethyl acetate (2000 ml) was stirred under an atmosphere of hydrogen for 18 hours. Removal of the catalyst by filtration, followed by solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-(3-

catalyst by filtration, followed by solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate (122 g, 100 % yield) as a brown oil :
¹H-NMR (DMSO d₆) : 7.15 (s, 1H), 6.4 (s, 2H), 6.35 (s, 1H), 4.2 (q, 2H), 3.95 (t, 2H), 3.65 (s, 3H), 3.55 (m, 4H), 2.4 (t, 2H), 2.35 (m, 4H), 1.85 (m, 2H), 1.25 (t, 3H) ;
MS (-ve ESI) : 337 (M-H),

15 MS (+ve ESI) : $339 (M+H)^+$.

e) A solution of ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate (130 g, 384 mmol) in formamide (280 ml) was heated at 180 °C for 3 hours, during which time a small amount (25 ml) of liquid distilled out of the reaction. The reaction was cooled to 125 °C and the excess formamide was evaporated *in vacuo*. Trituration of the solid residue with

isopropanol (100 ml), followed by drying *in vacuo*, yielded 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (83.0 g, 68 % yield) as a pale brown solid :
¹H-NMR (DMSO d₆) : 12.0 (s, 1H), 7.95 (s, 1H), 7.45 (s, 1H), 7.1 (s, 1H), 4.15 (t, 2H), 3.85 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.35 (m, 4H), 1.9 (m, 2H) :

MS (-ve ESI) : 318 (M-H)⁻,

25 MS (+ve ESI) : $320 (M+H)^{+}$.

f) Dimethylformamide (2.0 ml) was added dropwise to a solution of 6-methoxy-7-(3morpholinopropoxy)-3,4-dihydro-quinazolin-4-one (83.0 g, 261 mmol) in thionyl chloride (700ml) and the reaction was heated at reflux for 3.5 hours. The reaction was cooled, excess thionyl chloride was removed *in vacuo*, the residue was taken up in water (500 ml) and this aqueous solution was taken to pH 9 by addition of saturated aqueous sodium bicarbonate solution (300 ml). The aqueous phase was extracted with dichloromethane (2 x 400 ml), the



- 25 -

organic solution was washed with brine (400 ml) and the solvents were removed *in vacuo*. Trituration of the solid residue with ethyl acetate (150 ml), followed by drying *in vacuo*, yielded 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (53 g, 60 % yield) as a pale brown solid :

¹H-NMR (CDCl₃): 8.85 (s, 1H), 7.39 (s, 1H), 7.38 (s, 1H), 4.3 (t, 2H), 4.05 (s, 3H), 3.7 (m, 4H), 2.6 (t, 2H), 2.5 (m, 4H), 2.1 (m, 2H):
MS (+ve ESI): 338 (M+H)⁺.

Example 5

Preparation of Compound 5 in Table 1

An analogous reaction to that described in example 1, but starting with 4-chloro-6methoxy-7-(2,2,2-trifluoroethoxy)quinazoline (44 mg, 0.176 mmol), yielded the title compound (54 mg, 70 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 12.29 (s, 1H), 11.14 (s, 1H), 9.15 (s, 2H), 8.9 (s, 1H), 8.65 (s, 1H), 8.0 (d, 2H), 7.6 (m, 2H), 7.5 (m, 3H), 7.45 (s, 1H), 5.05 (dd, 2H), 4.05 (s, 3H) : MS (+ve ESI) : 471 (M+H)⁺.

4-Chloro-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline, used as starting material was obtained as follows :

20

10

15

a) Potassium carbonate (62.2 g, 450 mmol) was added to a solution of ethyl vanillate (58.9 g, 300 mmol) in dimethylformamide (400 ml) and the reaction heated to 120 °C. 2,2,2-Trifluoroethyl methanesulphonate (63.4 g, 360 mmol) was added over 15 minutes and the reaction heated at 120 °C for 15 hours. The reaction was cooled to ambient temperature, diethyl ether (400 ml) was added and the reaction was filtered. The filtrate was evaporated *in*

vacuo and the residue was taken up in a mixture of diethyl ether (375 ml) and isohexane (375 ml). The organic layer was concentrated in vacuo to a total volume of 250 ml and the solid which crystallised out was collected by suction filtration. Drying of the solid in vacuo yielded ethyl 4-(2,2,2-trifluoroethoxy)-3-methoxybenzoate (43.0 g, 52 % yield) as a white crystalline solid :

¹H-NMR (DMSO d₆) : 7.57 (dd, 1H, J = 2, 8 Hz), 7.49 (d, 1H, J = 2 Hz), 7.18 (d, 1H, J = 8 Hz), 5.81 (q, 2H, J = 7 Hz), 5.29 (q, 2H, J = 7 Hz), 3.82 (s, 3H), 1.30 (t, 3H, J = 7 Hz) :

5

10

- 26 -

MS (+ve ESI) : $279 (M+H)^{+}$.

b) Concentrated sulphuric acid (64 ml) and concentrated nitric acid (10.0 ml, 0.152 mol) were added cautiously, over 1 hour, to a two-phase system containing a stirred solution yielded ethyl 4-(2,2,2-trifluoroethoxy)-3-methoxybenzoate (35.3 g, 0.127 mol) in dichloromethane (340 ml), acetic acid (173 ml) and water (40 ml) at 5 °C. The reaction was allowed to warm to ambient temperature over 60 hours (with vigorous mechanical stirring), the aqueous phase was separated, and the organic phase washed with water (6 x 250 ml). The organic phase was

concentrated to a total volume of ~200 ml, isohexane (150 ml) was added and the solid which

precipitated out was collected by suction filtration. Drying of the solid *in vacuo*_yielded ethyl

3-methoxy-4-(2,2,2-trifluoroethoxy)-6-nitrobenzoate (21.7 g, 52 % yield) as a yellow solid. The mother liquors contained a mixture of product (28%) and starting material (72%) which was recycled in a latter reaction :

¹H-NMR (DMSO d_6) : 7.80 (s, 1H), 7.42 (s, 1H), 4.90 (q, 2H, J = 7 Hz), 4.20-4.35 (m, 2H), 4.00 (s, 3H), 1.32 (t, 3H, J = 7 Hz) :

15 MS (+ve ESI) : $324 (M+H)^+$.

c) A suspension of ethyl 3-methoxy-4-(2,2,2-trifluoroethoxy)-6-nitrobenzoate (24.0 g, 74.3 mmol) and 10% palladium on carbon (3.0 g) in a mixture of ethanol (100 ml) and ethyl acetate (750 ml) was stirred under an atmosphere of hydrogen for 18 hours. Removal of the catalyst by filtration, followed by solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-

20 (2,2,2-trifluoroethoxy)-6-aminobenzoate (20.2 g, 93 % yield) as a pale brown solid :
¹H-NMR (DMSO d₆) : 7.20 (s, 1H), 6.45 (s, 1H), 6.40 (s, 2H), 5.70 (q, 2H, J = 7 Hz), 4.20 (q, 2H, J = 7 Hz), 3.65 (s, 3H), 1.32 (t, 3H, J = 7 Hz) :

MS (-ve ESI) : 292 (M-H)⁻,

MS (+ve ESI) : 294 $(M+H)^{+}$.

- d) A mixture of ethyl 2-amino-4-(2,2,2-trifluoroethoxy)-5-methoxybenzoate (20.2 g, 69.1 mmol) and formamide (50ml) was heated at 175 °C for 6 hours. The mixture was allowed to cool to ambient temperature, ethanol (150 ml) was added and the reaction allowed to stand for 18 hours. Collection of the solid which had precipitated by suction filtration, followed by washing with ethanol (2 x 50 ml) and drying *in vacuo*, yielded 6-methoxy-7-(2,2,2-
- 30 trifluoroethoxy)-3,4-dihydroquinazolin-4-one (15.8 g, 84 % yield) as a pale brown crystalline solid :

5

10

15

20

25



¹H-NMR (DMSO d₆) : 12.10 (s, 1H), 8.00 (s, 1H), 7.51 (s, 1H), 7.30 (s, 1H), 4.90 (q, 2H, J = 7 Hz), 3.90 (s, 3H) :

MS (-ve ESI) : 273 (M-H)⁻,

MS (+ve ESI) : $275 (M+H)^{+}$.

e) Dimethylformamide (0.1 ml) was added dropwise to a solution yielded 6-methoxy-7-(2,2,2-trifluoroethoxy)-3,4-dihydroquinazolin-4-one (15.8 g, 57.7 mmol) in thionyl chloride (200ml) and the reaction was heated at reflux for 6 hours. The reaction was cooled, excess thionyl chloride was removed *in vacuo* and the residue was azeotroped with toluene (2 x 50 ml) to remove the last of the thionyl chloride. The residue was taken up in dichloromethane (550 ml), the solution was washed with saturated aqueous sodium hydrogen carbonate solution (2 x 250 ml) and the organic phase was dried over magnesium sulphate. Solvent evaporation *in vacuo* yielded 4-chloro-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline (16.3 g, 97 % yield) as a cream solid :

¹H-NMR (DMSO d_6) : 8.95 (s, 1H), 7.65 (s, 1H), 7.25 (s, 1H), 5.05 (q, 2H, J = 7 Hz), 4.00 (s, 3H) :

MS (+ve ESI) : 293, 295 $(M+H)^+$.

Example 6

Preparation of Compound 6 in Table 1

An analogous reaction to that described in example 1, but starting with 4-chloro-6methoxy-7-(3-morpholinopropoxy)quinazoline (50 mg, 0.15 mmol), yielded the title compound (26 mg, 30 % yield) as a white solid :

¹H-NMR (DMSO d₆) : 11.08 (s, 1H), 9.08 (s, 1H), 8.79 (s, 1H), 7.96-8.01 (m, 3H), 7.61 (t, 1H, J = 7 Hz), 7.52 (t, 2H, J = 7 Hz), 7.36 (s, 1H), 4.29 (t, 2H, J = 7 Hz), 4.00 (s, 3H), 3.60-3.71 (m, 2H), 3.49-3.58 (m, 2H), 3.33 (t, 2H, J = 7 Hz), 3.07-3.19 (m, 2H), 2.40-2.47 (m, 2H),

2.21-2.30 (m, 2H) :

MS (+ve ESI) : 516 $(M+H)^{+}$.

4-Chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline, used as the starting material, was obtained as follows :

a) A mixture of morpholine (261 ml, 3.00 mol) and 1-bromo-3-chloropropane (148 ml,
 1.50 mol) in toluene (900 ml) was stirred for 18 hours at ambient temperature. Additional 1-

- 28 -

bromo-3-chloropropane (25 ml, 0.25 mol) was added, the reaction was stirred for a further 1 hour and then filtered to remove the precipitated solid before the filtrate was concentrated *in vacuo*. Distillation of the crude oil yielded N-(3-chloropropyl)-morpholine (119.3 g, 49 % yield) as the fraction boiling at 70 - 80 °C / 2.6 mmHg :

5

¹H-NMR (DMSO d₆) : 3.65 (t, 2H), 3.55 (m, 4H), 2.4 (t, 2H), 2.39 (m, 4H), 1.85 (m, 2H) : MS (+ve ESI) : 164 (M+H)⁺.

b) N-(3-Chloropropyl)morpholine (90 g, 0.55 mol) was added dropwise, over 30 minutes, to a solution of ethyl vanillate (98 g, 0.50 mol) and powdered potassium carbonate (104 g, 0.75 mol) in dimethylformamide (300 ml) at 80 °C. The reaction was heated at 80 °C for 90

minutes, cooled to ambient temperature, filtered and the filtrate concentrated *in vacuo*. The crude product was taken up in diethyl ether (1000 ml), filtered and washed with water (2 x 200 ml) and brine (200 ml). Solvent evaporation in vacuo yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate (161.5 g, 100 % yield) as a pale yellow oil which crystallised on standing to afford a pale yellow solid :

¹H-NMR (DMSO d₆): 7.55 (dd, 1H), 7.4 (d, 1H), 7.05 (d, 1H), 4.3 (q, 2H), 4.05 (t, 2H), 3.8 (s, 3H), 3.55 (m, 4H), 2.4 (t, 2H), 2.35 (m, 4H), 1.9 (m, 2H), 1.3 (t, 3H):
MS (-ve ESI): 324 (M-H)⁻,

c) Concentrated sulphuric acid (110 ml) and concentrated nitric acid (19.0 ml, 0.289 mol) were added cautiously, over a 50 minute period, to a two-phase system containing a stirred

- 20 solution of ethyl 3-methoxy-4-(3-morpholinopropoxy)benzoate (76.5 g, 0.237 mol) in dichloromethane (600 ml), acetic acid (300 ml) and water (70 ml) at 5 °C. The reaction was allowed to warm to ambient temperature over 18 hours, the aqueous phase was separated, and the aqueous phase was taken to pH 9 by addition of 40% aqueous sodium hydroxide solution (775 ml). Extraction of the aqueous phase with dichloromethane (3 x 600 ml) and subsequent
- 25 solvent evaporation *in vacuo*_yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate (141.3 g, 86 % yield) as a yellow gum :
 ¹H-NMR (CDCl₃) : 7.5 (s, 1H), 7.1 (s, 1H), 4.4 (q, 2H), 4.2 (t, 2H), 4.0 (s, 3H), 3.7 (m, 4H), 2.5 (t, 2H), 2.45 (m, 4H), 2.05 (m, 2H), 1.4 (t, 3H) :
 MS (+ve ESI) : 369 (M+H)⁺.
- d) A suspension of ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-nitrobenzoate (132.2 g,
 359 mmol) and 10% palladium on carbon (3.0 g) in a mixture of ethanol (200 ml) and ethyl

5

0

15

- 29 -

acetate (2000 ml) was stirred under an atmosphere of hydrogen for 18 hours. Removal of the catalyst by filtration, followed by solvent evaporation *in vacuo* yielded ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate (122 g, 100 % yield) as a brown oil :

¹H-NMR (DMSO d₆) : 7.15 (s, 1H), 6.4 (s, 2H), 6.35 (s, 1H), 4.2 (q, 2H), 3.95 (t, 2H), 3.65 (s, 3H), 3.55 (m, 4H), 2.4 (t, 2H), 2.35 (m, 4H), 1.85 (m, 2H), 1.25 (t, 3H) ;

MS (-ve ESI) : 337 (M-H)⁻,

MS (+ve ESI) : $339 (M+H)^{+}$.

e) A solution of ethyl 3-methoxy-4-(3-morpholinopropoxy)-6-aminobenzoate (130 g, 384 mmol) in formamide (280 ml) was heated at 180 °C for 3 hours, during which time a small amount (25 ml) of liquid distilled out of the reaction. The reaction was cooled to 125 °C and the excess formamide was evaporated *in vacuo*. Trituration of the solid residue with isopropanol (100 ml), followed by drying *in vacuo*, yielded 6-methoxy-7-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (83.0 g, 68 % yield) as a pale brown solid : ¹H-NMR (DMSO d₆) : 12.0 (s, 1H), 7.95 (s, 1H), 7.45 (s, 1H), 7.1 (s, 1H), 4.15 (t, 2H), 3.85 (s, 3H), 3.6 (m, 4H), 2.45 (t, 2H), 2.35 (m, 4H), 1.9 (m, 2H) :

MS (-ve ESI) : 318 (M-H),

MS (+ve ESI) : $320 (M+H)^{+}$.

f) Dimethylformamide (2.0 ml) was added dropwise to a solution of 6-methoxy-7-(3morpholinopropoxy)-3,4-dihydro-quinazolin-4-one (83.0 g, 261 mmol) in thionyl chloride (700ml) and the reaction was heated at reflux for 3.5 hours. The reaction was cooled, excess thionyl chloride was removed *in vacuo*, the residue was taken up in water (500 ml) and this aqueous solution was taken to pH 9 by addition of saturated aqueous sodium bicarbonate solution (300 ml). The aqueous phase was extracted with dichloromethane (2 x 400 ml), the organic solution was washed with brine (400 ml) and the solvents were removed *in vacuo*.

25 Trituration of the solid residue with ethyl acetate (150 ml), followed by drying *in vacuo*, yielded 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (53 g, 60 % yield) as a pale brown solid :

¹H-NMR (CDCl₃) : 8.85 (s, 1H), 7.39 (s, 1H), 7.38 (s, 1H), 4.3 (t, 2H), 4.05 (s, 3H), 3.7 (m, 4H), 2.6 (t, 2H), 2.5 (m, 4H), 2.1 (m, 2H) :

30 MS (+ve ESI) : 338 $(M+H)^+$.

- 30 -

Example 7

Preparation of Compound 7 in Table 1

A solution of 1.0N hydrochloric acid in ether (0.50 ml, 0.50 mmol) was added to a solution of 5-amino-2-(pyrid-3-yloxy)pyridine (94 mg, 0.50 mmol) and 4-chloro-6-methoxy-7-

- (3-morpholinopropoxy)quinazoline (168 mg, 0.50 mmol), in isopropanol (5.0 ml). The 5 reaction was heated at 40 °C for 30 minutes and then at 83 °C for 12 hours. The reaction was allowed to cool to ambient temperature and the solid which had precipitated was collected by suction filtration and washed with diethyl ether (2 x 10 ml). Drying of this material yielded the title compound (253 mg, 96 % yield) as a white solid :
- ¹H-NMR (DMSO d_6) : 11.77 (s, 1H), 11.08 (s, 1H), 8.83 (s, 1H), 8.55 (s, 1H), 8.48 (m, 3H), 10 8.27 (d, 1H), 7.75 (m, 1H), 7.56 (m, 1H), 7.43 (s, 1H), 7.30 (d, 1H), 4.32 (t, 2H), 4.05 (s, 3H), 3.95 (m, 2H), 3.82 (m, 2H), 3.5 (m, 2H), 3.3 (m, 2H), 3.1 (m, 2H), 2.35 (m, 2H) : MS (+ve ESI) : $489 (M+H)^{+}$.

Example 8 15

Preparation of Compound 8 in Table 1

An analogous reaction to that described in example 21, but starting with 5-amino-2-(4chlorophenoxy)pyridine (110 mg, 0.50 mmol) yielded the title compound (261 mg, 94 % yield) as a white solid :

¹H-NMR (DMSO d₄) : 11.7 (s, 1H), 11.02 (s, 1H), 8.82 (s, 1H), 8.5 (d, 2H), 8.22 (d, 1H), 7.52 20 (d, 2H), 7.45 (s, 1H), 7.25 (s, 1H), 7.22 (d, 2H), 4.35 (t, 2H), 4.05 (s, 3H), 3.98 (m, 2H), 3.85 (m, 2H), 3.50 (m, 2H), 3.35 (m, 2H), 3.10 (m, 2H), 2.35 (m, 2H) : MS (+ve ESI) : $524 (M+H)^{+}$.

Example 9 25

30

Preparation of Compound 9 in Table 1

An analogous reaction to that described in example 1, but starting with 5-amino-2-(4chlorophenoxy)pyridine (110 mg, 0.50 mmol) and 4-chloro-6-methoxy-7-

benzyloxyquinazoline (150 g, 0.50 mmol), yielded the title compound (242 mg, 93 % yield) as a white solid :

- 31 -

¹H-NMR (DMSO d₆) : 11.60 (s, 1H), 8.81 (s, 1H), 8.50 (s, 1H), 8.40 (s, 1H), 8.20 (d, 1H), 7.36-7.59 (m, 8H), 7.18-7.30 (m, 3H), 5.35 (s, 2H), 4.04 (s, 3H) : MS (+ve ESI) : 485 (M+H)⁺.

4-Chloro-6-methoxy-7-benzyloxyquinazoline, used as the starting material, was obtained as follows :

5 follows :

0

a) A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (10g, 0.04mol), (prepared according *to J. Med. Chem.* 1977, *20*, 146-149), and Gold's reagent (7.4g, 0.05mol) in dioxane (100ml) was stirred and heated at reflux for 24 hours. Sodium acetate (3.02g, 0.037mol) and acetic acid (1.65ml, 0.029mol) were added to the reaction mixture and it was heated for a further 3 hours. The volatiles were removed by evaporation, water was added to the residue, the solid was collected by filtration, washed with water and dried. Recrystallisation from acetic acid yielded 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7g, 84 % yield) as a white solid:

b) Dimethylformamide (0.2 ml) was added dropwise to a solution of 6-methoxy-7-

benzyloxy-3,4-dihydroquinazolin-4-one (5.00 g, 17.9 mmol) in thionyl chloride (100ml) and the reaction was heated at reflux for 1 hour. The reaction was cooled, excess thionyl chloride was removed *in vacuo* and the residue was azeotroped with toluene (3 x 50 ml) to remove the last of the thionyl chloride. The residue was taken up in dichloromethane (550 ml), the solution was washed with saturated aqueous sodium hydrogen carbonate solution (100 ml)and water (100 ml) and the organic phase was dried over magnesium sulphate. Solvent evaporation *in vacuo* yielded 4-chloro-6,7-dimethoxyquinazoline (4.80 g, 90 % yield) as a pale brown solid :

¹H-NMR (DMSO d₆) : 8.85 (s,1H), 7.58 (s, 1H), 7.5 (d, 2H), 7.4 (m, 4H), 5.35 (s, 2H), 4.0 (s, 3H) :

25 MS (+ve ESI) : $301 (M+H)^+$.

Example 10

Preparation of Compound 10 in Table 1

An analogous reaction to that described in example 9, but starting with 5-amino-2-(pyrid-3-yloxy)pyridine (94 mg, 0.50 mmol) yielded the title compound (224 mg, 92 % yield) as a white solid : - 32 -

¹H-NMR (DMSO d₆) : 11.55 (s, 1H), 8.80 (s, 1H), 8.55 (s, 1H), 8.45 (d, 2H), 8.38 (s, 1H), 8.25 (d, 1H), 7.75 (m, 1H), 7.51 (m, 3H), 7.40 (m, 4H), 7.30 (d, 1H), 5.35 (s, 2H), 4.05 (s, 3H) : MS (+ve ESI) : 452 (M+H)⁺.

5 Biological Data

The compounds of the invention inhibit the serine/threonine kinase activity of the aurora2 kinase and thus inhibit the cell cycle and cell proliferation. These properties may be assessed, for example, using one or more of the procedures set out below:

10 (a) In Vitro aurora2 kinase inhibition test

This assay determines the ability of a test compound to inhibit serine/threonine kinase activity. DNA encoding aurora2 may be obtained by total gene synthesis or by cloning. This DNA may then be expressed in a suitable expression system to obtain polypeptide with serine/threonine kinase activity. In the case of aurora2, the coding sequence was isolated from cDNA by polymerase chain reaction (PCR) and cloned into the BamH1 and Not1 restriction endonuclease sites of the baculovirus expression vector pFastBac HTc (GibcoBRL/Life technologies). The 5' PCR primer contained a recognition sequence for the restriction endonuclease BamH1 5' to the aurora2 coding sequence. This allowed the insertion of the aurora2 gene in frame with the 6 histidine residues, spacer region and rTEV protease cleavage site encoded by the pFastBac HTc vector. The 3' PCR primer replaced the aurora2 stop codon with additional coding sequence followed by a stop codon and a recognition sequence for the restriction endonuclease Not1 . This additional coding sequence (5' TAC CCA TAC GAT GTT CCA GAT TAC GCT TCT TAA 3') encoded for the polypeptide sequence

YPYDVPDYAS. This sequence, derived from the influenza hemagglutin protein, is frequently used as a tag epitope sequence that can be identified using specific monoclonal antibodies. The recombinant pFastBac vector therefore encoded for an N-terminally 6 his tagged, C terminally influenza hemagglutin epitope tagged aurora2 protein. Details of the methods for the assembly of recombinant DNA molecules can be found in standard texts, for
 example Sambrook et al. 1989, Molecular Cloning - A Laboratory Manual, 2nd Edition, Cold

15

PHM_99-140

Spring Harbor Laboratory press and Ausubel et al. 1999, Current Protocols in Molecular Biology, John Wiley and Sons Inc.

- 33 -

Production of recombinant virus can be performed following manufacturer's protocol from GibcoBRL. Briefly, the pFastBac-1 vector carrying the aurora2 gene was transformed into E. coli DH10Bac cells containing the baculovirus genome (bacmid DNA) and via a transposition event in the cells, a region of the pFastBac vector containing gentamycin resistance gene and the aurora2 gene including the baculovirus polyhedrin promoter was transposed directly into the bacmid DNA. By selection on gentamycin, kanamycin, tetracycline and X-gal, resultant white colonies should contain recombinant bacmid DNA encoding aurora2. Bacmid DNA was extracted from a small scale culture of several BH10Bac white colonies and transfected into Spodoptera frugiperda Sf21 cells grown in TC100 medium (GibcoBRL) containing 10% serum using CellFECTIN reagent (GibcoBRL) following manufacturer's instructions. Virus particles were harvested by collecting cell culture medium 72 hrs post transfection. 0.5 mls of medium was used to infect 100 ml suspension culture of Sf21s containing 1 x 10⁷ cells/ml. Cell culture medium was harvested 48 hrs post infection and virus titre determined using a standard plaque assay procedure. Virus stocks were used to infect Sf9 and "High 5" cells at a

multiplicity of infection (MOI) of 3 to ascertain expression of recombinant aurora2 protein. For the large scale expression of aurora2 kinase activity, Sf21 insect cells were grown at 28°C in TC100 medium supplemented with 10% foetal calf serum (Viralex) and 0.2% F68
Pluronic (Sigma) on a Wheaton roller rig at 3 r.p.m. When the cell density reached 1.2x10⁶ cells ml⁻¹ they were infected with plaque-pure aurora2 recombinant virus at a multiplicity of infection of 1 and harvested 48 hours later. All subsequent purification steps were performed at 4°C. Frozen insect cell pellets containing a total of 2.0 x 10⁸ cells were thawed and diluted with lysis buffer (25 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic

acid]) pH7.4 at 4°C , 100 mM KCl, 25 mM NaF, 1 mM Na₃VO₄, 1 mM PMSF (phenylmethylsulphonyl fluoride), 2 mM 2-mercaptoethanol, 2 mM imidazole, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1 µg/ml leupeptin), using 1.0 ml per 3 x 10⁷ cells. Lysis was achieved using a dounce homogeniser, following which the lysate was centrifuged at 41,000g for 35 minutes. Aspirated supernatant was pumped onto a 5 mm diameter chromatography column containing 500 µl Ni NTA (nitrilo-tri-acetic acid) agarose (Qiagen, product no. 30250) which had been equilibrated in lysis buffer. A baseline level of UV absorbance for the

15

20

ło

10

15

20

25

- 34 -

eluent was reached after washing the column with 12 ml of lysis buffer followed by 7 ml of wash buffer (25 mM HEPES pH7.4 at 4°C, 100 mM KCl, 20 mM imidazole, 2 mM 2mercaptoethanol). Bound aurora2 protein was eluted from the column using elution buffer (25 mM HEPES pH7.4 at 4°C, 100 mM KCl, 400 mM imidazole, 2 mM 2-mercaptoethanol). An

5 elution fraction (2.5 ml) corresponding to the peak in UV absorbance was collected. The elution fraction, containing active aurora2 kinase, was dialysed exhaustively against dialysis buffer (25 mM HEPES pH7.4 at 4°C, 45% glycerol (v/v), 100 mM KCl, 0.25% Nonidet P40 (v/v), 1 mM dithiothreitol).

Each new batch of aurora2 enzyme was titrated in the assay by dilution with enzyme diluent (25mM Tris-HCl pH7.5, 12.5mM KCl, 0.6mM DTT). For a typical batch, stock enzyme is diluted 1 in 666 with enzyme diluent & 20µl of dilute enzyme is used for each assay well. Test compounds (at 10mM in dimethylsulphoxide (DMSO)) were diluted with water & 10µl of diluted compound was transferred to wells in the assay plates. "Total" & "blank" control wells contained 2.5% DMSO instead of compound. Twenty microlitres of freshly diluted enzyme was added to all wells, apart from "blank" wells. Twenty microlitres of enzyme diluent was added to "blank" wells. Twenty microlitres of reaction mix (25mM Tris-HCl, 78.4mM KCl, 2.5mM NaF, 0.6mM dithiothreitol, 6.25mM MnCl₂, 6.25mM ATP, 7.5µM peptide substrate [biotin-LRRWSLGLRRWSLGLRRWSLGLRRWSLG]) containing $0.2\mu Ci [\gamma^{33}P]ATP$ (Amersham Pharmacia, specific activity $\geq 2500Ci/mmol$) was then added to all test wells to start the reaction. The plates were incubated at room temperature for 60 minutes. To stop the reaction 100µl 20% v/v orthophosphoric acid was added to all wells. The peptide substrate was captured on positively-charged nitrocellulose P30 filtermat (Whatman) using a 96-well plate harvester (TomTek) & then assayed for incorporation of ³³P with a Beta plate counter. "Blank" (no enzyme) and "total" (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibition of enzyme activity.

In this test, compound 1 in Table 1 gave 50% inhibition of enzyme activity at a concentration of $0.00785 \mu M$.

(b) In Vitro cell proliferation assay

30 This assay determines the ability of a test compound to inhibit the growth of adherent mammalian cell lines, for example the human tumour cell line MCF7. - 35 -

MCF-7 (ATCC HTB-22) or other adherent cells were typically seeded at 1 x 10³ cells per well (excluding the peripheral wells) in DMEM (Sigma Aldrich) without phenol red, plus 10% foetal calf serum, 1% L-glutamine and 1% penicillin/streptomycin in 96 well tissue culture treated clear plates (Costar). The following day (day 1), the media was removed from a no treatment control plate and the plate stored at -80°C. The remaining plates were dosed with compound (diluted from 10mM stock in DMSO using DMEM (without phenol red, 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin). Untreated control wells were included on each plate. After 3 days in the presence / absence of compound (day 4) the media was removed and the plates stored at -80°C. Twenty four hours later the plates were thawed at room temperature and cell density determined using the CyQUANT cell proliferation assay kit (c-7026/c-7027 Molecular Probes Inc.) according to manufacturers directions. Briefly, 200µl of a cell lysis / dye mixture (10µl of 20X cell lysis buffer B, 190µl of sterile water, 0.25µl of CYQUANT GR dye) was added to each well and the plates incubated at room temperature for 5 minutes in the dark. The fluorescence of the wells was then measured using a fluorescence microplate reader (gain 70, 2 reads per well, 1 cycle with excitation 485nm and emission 530nm using a CytoFluor plate reader (PerSeptive Biosystems Inc.)). The values from day 1 and day 4 (compound treated) together with the values from the untreated cells were used to determine the dilution range of a test compound that gave 50% inhibition of cell proliferation. Compound 1 in Table 1 was effective in this test at $1.7\mu M$

These values could also be used to calculate the dilution range of a test compound at which the cell density dropped below the day 1 control value. This indicates the cytotoxicity of the compound.

(c) In Vitro cell cycle analysis assay

25

30

5

10

15

80

This assay determines the ability of a test compound to arrest cells in specific phases of the cell cycle. Many different mammalian cell lines could be used in this assay and MCF7 cells are included here as an example. MCF-7 cells were seeded at 3×10^5 cells per T25 flask (Costar) in 5 ml DMEM (no phenol red 10% FCS, 1% L-glutamine 1% penicillin / streptomycin). Flasks were then incubated overnight in a humidified 37° C incubator with 5% CO₂. The following day 1ml of DMEM (no phenol red 10% FCS, 1% L-glutamine 1%)

PHM 99-140

penicillin / streptomycin) carrying the appropriate concentration of test compound solubilised in DMSO was added to the flask . A no compound control treatments was also included (0.5% DMSO). The cells were then incubated for a defined time (usually 24 hours) with compound. After this time the media was aspirated from the cells and they were washed with 5ml of prewarmed (37° C) sterile PBSA, then detached from the flask by brief incubation with trypsin and followed by resuspension in 10ml of 1% Bovine Serum Albumin (BSA, Sigma-Aldrich Co.) in sterile PBSA. The samples were then centrifuged at 2200rpm for 10 min. The supernatant was aspirated and the cell pellet was resuspended in 200µl of 0.1% (w/v) Tris sodium citrate, 0.0564% (w/v) NaCl, 0.03% (v/v) Nonidet NP40, [pH 7.6]. Propridium Iodide (Sigma Aldrich Co.) was added to 40µg/ml and RNAase A (Sigma Aldrich Co.) to 100µg/ml. The cells were then incubated at 37°C for 30 minutes. The samples were centrifuged at 2200rpm for 10 min, the supernatant removed and the remaining pellet (nuclei) resuspended in 200µl of sterile PBSA. Each sample was then syringed 10 times using 21 gauge needle. The samples were then transferred to LPS tubes and DNA content per cell analysed by Fluorescence activated cell sorting (FACS) using a FACScan flow cytometer (Becton Di Li anal). Trainelly 26000 musta upper approximate and respected uping CellQuester la activated cell sorting (FACS) using a FACScan flow cytometer (Becton

- 36 -

- 15 Fluorescence activated cell sorting (FACS) using a FACScan flow cytometer (Becton Dickinson). Typically 25000 events were counted and recorded using CellQuest v1.1 software (Verity Software). Cell cycle distribution of the population was calculated using Modfit software (Verity Software) and expressed as percentage of cells in G0/G1, S and G2/M phases of the cell cycle.
- 20

5

10

Treating MCF7 cells with 10µM Compound 1 in Table 1 for 24 hours produced the following changes in cell cycle distribution:

Treatment	% Cells in	% Cells in S	% Cells in G2/M
	G1		
DMSO (control)	74.29	20	5.97
10µM Compound 1	43.22	18	30.38

. . <u>. .</u> . .